| $350M | ||
| $172M | ||
| $127M | ||
| $109M | ||
| $107M | ||
| $100M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Lisata Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on pioneering and bringing to market cellular therapies. These treatments are designed to either reverse disease progression or facilitate the repair of damaged bodily tissues. The company's product portfolio features several notable candidates: HONEDRA, which has received SAKIGAKE designation and is presently in Phase II clinical trials for critical limb ischemia; XOWNA, currently undergoing Phase IIb testing for coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy aimed at individuals with chronic kidney disease who are not yet on dialysis. Founded in 1980 and based in Basking Ridge, New Jersey, the company was initially known as NeoStem, Inc., then rebranded as Caladrius Biosciences, Inc. in June 2015, before assuming its present identity as Lisata Therapeutics, Inc. on September 15, 2022.
Over the last 12 months, insiders at Lisata Therapeutics, Inc. have bought $0 and sold $0 worth of Lisata Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Lisata Therapeutics, Inc. have bought $30,190 and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 33,785 shares for transaction amount of $30,190 was made by MYERS STEVEN S (director) on 2021‑12‑08.
| MYERS STEVEN S | director | 146839 1.6125% | $278,994.10 | 1 | 0 | <0.0001% |
$18,815,063 | 62 | -6.45% | $14.78M | |
$1,993,425 | 46 | -21.91% | $16.37M | |
$95,344,010 | 36 | -18.97% | $15.87M | |
$30,257,839 | 29 | -15.72% | $20.16M | |
$26,786,140 | 22 | -18.62% | $16.39M | |
$555,628 | 21 | 43.52% | $18.55M | |
$114,619,342 | 20 | -7.41% | $20.17M | |
$742,412 | 14 | -50.36% | $19.04M | |
$1,246,170 | 12 | 65.67% | $20.02M | |
$365,792 | 12 | -15.77% | $18.9M | |
$684,058 | 11 | -57.59% | $14M | |
$4,146,041 | 11 | -40.86% | $16.56M | |
$4,176,565 | 9 | 18.77% | $21.94M | |
$654,995 | 7 | -60.00% | $19.89M | |
$56,660 | 7 | -68.80% | $12.1M | |
$5,117,729 | 6 | -52.29% | $14.52M | |
$2,060,158 | 5 | -21.35% | $17.1M | |
$1,124,966 | 4 | 0.87% | $18.73M | |
Lisata Therapeutics, Inc. (LSTA) | $30,190 | 1 | -42.39% | $17.3M |
| Increased Positions | 13 | +56.52% | 30,832 | +4.1% |
| Decreased Positions | 8 | -34.78% | 54,934 | -7.31% |
| New Positions | 6 | New | 6,080 | New |
| Sold Out Positions | 2 | Sold Out | 11,115 | Sold Out |
| Total Postitions | 28 | +21.74% | 727,244 | -3.21% |
| Vanguard Group Inc | $530.00 | 3.01% | 270,514 | +16,332 | +6.42% | 2025-09-30 |
| Renaissance Technologies Llc | $229.00 | 1.3% | 116,622 | +13,800 | +13.42% | 2025-09-30 |
| Bml Capital Management, Llc | $215.00 | 1.22% | 109,841 | -99,973 | -47.65% | 2025-09-30 |
| Geode Capital Management, Llc | $124.00 | 0.7% | 63,260 | +2,178 | +3.57% | 2025-09-30 |
| Blackrock, Inc. | $108.00 | 0.61% | 54,890 | +33 | +0.06% | 2025-09-30 |
| Ground Swell Capital, Llc | $47.00 | 0.26% | 23,774 | +23,774 | New | 2025-09-30 |
| Dimensional Fund Advisors Lp | $41.00 | 0.23% | 20,947 | -4,846 | -18.79% | 2025-09-30 |
| State Street Corp | $28.00 | 0.16% | 14,348 | 0 | 0% | 2025-09-30 |
| Cerity Partners Llc | $24.00 | 0.14% | 12,183 | 0 | 0% | 2025-09-30 |
| Cook Wealth, Llc | $24.00 | 0.14% | 12,175 | 0 | 0% | 2025-03-31 |